metformin has been researched along with Abnormalities, Drug-Induced in 12 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether metformin would safely reduce the rate of first-trimester spontaneous abortion without teratogenicity in 19 women with the polycystic ovary syndrome (PCOS)." | 9.09 | Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. ( Cameron, D; Glueck, CJ; Phillips, H; Sieve-Smith, L; Wang, P, 2001) |
| "To conduct a systematic review and meta-analysis of pregnancy outcome after metformin use for polycystic ovary syndrome (PCOS), because the efficacy of metformin has been demonstrated in the treatment of infertility caused by PCOS, whereas the fetal safety of metformin has received very little attention, and the few studies addressing this issue are limited by small sample sizes." | 8.83 | Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. ( Gilbert, C; Koren, G; Valois, M, 2006) |
| "To investigate whether exposure to metformin during the first trimester of pregnancy, for diabetes or other indications, increases the risk of all or specific congenital anomalies." | 7.88 | Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. ( Addor, MC; Bakker, M; Bertaut-Nativel, B; Dolk, H; Garne, E; Gatt, M; Given, JE; Klungsoyr, K; Lelong, N; Loane, M; Morgan, M; Neville, AJ; Pierini, A; Rissmann, A, 2018) |
| "The aim of this study was to evaluate the risk of major birth defects and spontaneous abortion after metformin use during the first trimester of pregnancy." | 7.88 | Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study. ( Beck, E; Grupe, K; Schaefer, C; Scherneck, S; Schlinke, N; Weber-Schoendorfer, C, 2018) |
| "Polycystic ovary syndrome is characterized among other things by oligo-amenorrhea and may account for more than 75% of cases with anoluvatory infertility." | 6.43 | Is metformin therapy for polycystic ovary syndrome safe during pregnancy? ( Brock, B; Ovesen, P; Rungby, J; Schmitz, O; Smidt, K, 2005) |
| "To determine whether metformin would safely reduce the rate of first-trimester spontaneous abortion without teratogenicity in 19 women with the polycystic ovary syndrome (PCOS)." | 5.09 | Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. ( Cameron, D; Glueck, CJ; Phillips, H; Sieve-Smith, L; Wang, P, 2001) |
| "To conduct a systematic review and meta-analysis of pregnancy outcome after metformin use for polycystic ovary syndrome (PCOS), because the efficacy of metformin has been demonstrated in the treatment of infertility caused by PCOS, whereas the fetal safety of metformin has received very little attention, and the few studies addressing this issue are limited by small sample sizes." | 4.83 | Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. ( Gilbert, C; Koren, G; Valois, M, 2006) |
| "To investigate whether exposure to metformin during the first trimester of pregnancy, for diabetes or other indications, increases the risk of all or specific congenital anomalies." | 3.88 | Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. ( Addor, MC; Bakker, M; Bertaut-Nativel, B; Dolk, H; Garne, E; Gatt, M; Given, JE; Klungsoyr, K; Lelong, N; Loane, M; Morgan, M; Neville, AJ; Pierini, A; Rissmann, A, 2018) |
| "The aim of this study was to evaluate the risk of major birth defects and spontaneous abortion after metformin use during the first trimester of pregnancy." | 3.88 | Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study. ( Beck, E; Grupe, K; Schaefer, C; Scherneck, S; Schlinke, N; Weber-Schoendorfer, C, 2018) |
| "Polycystic ovary syndrome is characterized among other things by oligo-amenorrhea and may account for more than 75% of cases with anoluvatory infertility." | 2.43 | Is metformin therapy for polycystic ovary syndrome safe during pregnancy? ( Brock, B; Ovesen, P; Rungby, J; Schmitz, O; Smidt, K, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wadman, M | 1 |
| Kjerpeseth, LJ | 1 |
| Cesta, CE | 1 |
| Furu, K | 1 |
| Engeland, A | 1 |
| Gissler, M | 1 |
| Gulseth, HL | 1 |
| Karlstad, Ø | 1 |
| Leinonen, MK | 1 |
| Pazzagli, L | 1 |
| Zoega, H | 1 |
| Cohen, JM | 1 |
| Kelty, E | 1 |
| Tran, DD | 1 |
| Atkinson, A | 1 |
| Preen, DB | 1 |
| Havard, A | 1 |
| Dukhovny, S | 1 |
| Van Bennekom, CM | 1 |
| Gagnon, DR | 1 |
| Hernandez Diaz, S | 1 |
| Parker, SE | 1 |
| Anderka, M | 1 |
| Werler, MM | 1 |
| Mitchell, AA | 1 |
| Given, JE | 1 |
| Loane, M | 1 |
| Garne, E | 1 |
| Addor, MC | 1 |
| Bakker, M | 1 |
| Bertaut-Nativel, B | 1 |
| Gatt, M | 1 |
| Klungsoyr, K | 1 |
| Lelong, N | 1 |
| Morgan, M | 1 |
| Neville, AJ | 1 |
| Pierini, A | 1 |
| Rissmann, A | 1 |
| Dolk, H | 1 |
| Scherneck, S | 1 |
| Schlinke, N | 1 |
| Beck, E | 1 |
| Grupe, K | 1 |
| Weber-Schoendorfer, C | 1 |
| Schaefer, C | 1 |
| Andrade, C | 1 |
| Brock, B | 1 |
| Smidt, K | 1 |
| Ovesen, P | 1 |
| Schmitz, O | 1 |
| Rungby, J | 1 |
| Gilbert, CJ | 1 |
| Koren, G | 2 |
| Gilbert, C | 1 |
| Valois, M | 1 |
| Glueck, CJ | 1 |
| Phillips, H | 1 |
| Cameron, D | 1 |
| Sieve-Smith, L | 1 |
| Wang, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Effects of Metformin on Fertility and Pregnancy in Women With Polycystic Ovary Syndrome: a Randomized, Prospective, Placebo-controlled Multicenter Study[NCT00994812] | Phase 3 | 326 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for metformin and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Major malformation risk, pregnancy outcomes, and neurodevelopmental outcomes associated with metformin use during pregnancy.
Topics: Abnormalities, Drug-Induced; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Infan | 2016 |
Is metformin therapy for polycystic ovary syndrome safe during pregnancy?
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Anencephaly; Animals; Anophthalmos; Blastocyst; | 2005 |
Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Canada; Comorbidity; Female; Humans; Hypoglycemic Agents; Incidence; Me | 2006 |
1 trial available for metformin and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Birth Weight; Female; Health Status Indic | 2001 |
8 other studies available for metformin and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Genital defects seen in sons of men taking major diabetes drug.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Diabetes Mellitus; Fertilization; Genitalia, Male; H | 2022 |
Metformin Versus Insulin and Risk of Major Congenital Malformations in Pregnancies With Type 2 Diabetes: A Nordic Register-Based Cohort Study.
Topics: Abnormalities, Drug-Induced; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Ins | 2023 |
Maternal and Neonatal Health Outcomes Associated with the Use of Gliclazide and Metformin for the Treatment of Diabetes in Pregnancy: A Record Linkage Study.
Topics: Abnormalities, Drug-Induced; Adult; Diabetes, Gestational; Female; Gliclazide; Hospitalization; Huma | 2020 |
Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study.
Topics: Abnormalities, Drug-Induced; Adult; Female; Humans; Hypoglycemic Agents; Logistic Models; Metformin; | 2018 |
Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study.
Topics: Abnormalities, Drug-Induced; Adult; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Mater | 2018 |
Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Diabetes Mellitus, Type 2; Fe | 2018 |
Dutasteride (Avodart) for benign prostatic hyperplasia.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Azasteroids; Biological Availability; Clinical Tr | 2002 |
Safety of metformin use during the first trimester.
Topics: Abnormalities, Drug-Induced; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy; Pregnancy Tr | 2005 |